Results 221 to 230 of about 15,755,427 (366)

Cancer Trends: Hodgkin’s lymphoma

, 2013
An average of 101 cases of Hodgkin’s lymphoma (HL) was diagnosed per year in Ireland between 1994 and 2011, equating to an incidence rate of 2.5 cases per 100,000 per year (Table 1).
National Cancer Registry Ireland (NCRI)
core  

Green nanomedicine for cancer therapy. [PDF]

Chin Med J (Engl)
Liu W, Fan B, Qian Y, Shi H, Zhang H, Zhang X.   +5 more
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Curcumin as a Synergy Amplifier in Cancer Therapy. [PDF]

Pharmaceutics
Mumtaz S, Rana JN, Gul K.
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Is Routine Postoperative Day 1 MAG3 Renal Scintigraphy Necessary After Living-Donor Kidney Transplantation?

Advances in Urology
Tomoyuki Makino, Takahiro Nohara, Ren Toriumi, Ryunosuke Nakagawa, Renato Naito, Hiroaki Iwamoto, Kouji Izumi, Atsushi Mizokami   +7 more
doaj   +1 more source

Stimuli-responsive bioengineered platforms for precision cancer therapy. [PDF]

Front Bioeng Biotechnol
Omidian H, Wilson RL.
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Erratum: Ferroptosis and circular RNAs: new horizons in cancer therapy. [PDF]

EXCLI J
Bhat AA, Kukreti N, Afzal M, Goyal A, Thapa R, Ali H, Shahwan M, Almalki WH, Kazmi I, Alzarea SI, Singh SK, Dua K, Gupta G.   +12 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source